Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tinengotinib - TransThera Biosciences

Next Previous
X
Search
Drug Profile

Tinengotinib - TransThera Biosciences

Alternative Names: TT 00420

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransThera Biosciences
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Morpholines; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase I/II Prostate cancer; Solid tumours
  • No development reported Triple negative breast cancer

Most Recent Events

  • 09 Dec 2024 Updated efficacy and adverse events data from a phase Ib/II trial in Solid tumours released by TransThera Biosciences
  • 04 Jun 2024 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO) (NCT06457919)
  • 22 Apr 2024 TransThera Sciences initiates an expanded-access programme for Solid tumour (Late-stage disease, Monotherapy) in USA (PO) (NCT06370013)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top